The level of circulating immune complexes (CIC) was studied before and after treatment in a group of 86 patients with multiple sclerosis (MS) (36 males and 50 females) ranging in age between 20 and 30 years and in 32 controls. CIC determinations were performed both in the serum and in the CSF, using the method of precipitation in polyethylene glycol (PEG). In 61.62% of the patients the mean serum CIC values (82.44 ODU; p = 0.01) exceeded those found in the controls (60.1 ODU) while the CSF mean CIC values (21.63 ODU; p = 0.05) exceeded those in the controls in 59.30% of the patients (12.8 ODU). The prevalence of patients with CIC values exceeding the control values presented variations according to the clinical stage of disease. Thus in the acute stage 83.33% of the patients presented the highest mean serum CIC values (110.5 ODU; p = 0.05) and 100% of the patients presented the highest mean CSF CIC values (27.9 ODU). After treatment it was observed that the prevalence of patients with high CIC values decreased. In conclusion it was observed that there is a correlation between the prevalence of patients with increased CIC values in the serum and CSF, and the clinical stage and treatment administered. This observation suggests that CIC determinations both in the serum and in the CSF may constitute an immunologic marker in MS.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the predictive value of CSF-restricted oligoclonal bands on residual disability and risk of relapse in adult patients with MOGAD: MOGADOC study.
Mult Scler
January 2025
Service de Neurologie, Sclérose en Plaques, Pathologie de la Myéline et Neuro-Inflammation, Hopital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.
Background: The clinical course of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is variable. However, robust markers of poor outcome and/or relapse risk are still missing.
Objective: To evaluate the frequency of cerebrospinal fluid-restricted oligoclonal bands (CSF-OCB) in a national cohort of adult MOGAD patients and to assess their prognostic value for the risk of relapse and severity.
Stanniocalcin 1 in patients with refractory colorectal cancer treated with regorafenib: A post-hoc biomarker analysis of the TEXCAN and CORRECT trials.
Cancer Res Commun
January 2025
university hospital of besançon, Besancon, France.
Biomarkers for anti-angiogenic drugs in chemo-refractory metastatic colorectal cancer (mCRC) are lacking. We investigated the relationship between stanniocalcin 1 (STC1) and outcomes in patients treated with regorafenib in the TEXCAN and CORRECT trials. Baseline plasma STC1 protein levels were measured by ELISA from patients with chemo-refractory mCRC enrolled in TEXCAN (regorafenib n=48) and CORRECT (placebo n=211; regorafenib n=435).
View Article and Find Full Text PDFEchocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial.
Cardiovasc Diabetol
January 2025
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Diabetic myocardial disorder (DbMD, evidenced by abnormal echocardiography or cardiac biomarkers) is a form of stage B heart failure (SBHF) at high risk for progression to overt HF. SBHF is defined by abnormal LV morphology and function and/or abnormal cardiac biomarker concentrations.
Objective: To compare the evolution of four DbMD groups based on biomarkers alone, systolic and diastolic dysfunction alone, or their combination.
Efficacy of the Roy Adaptation Model with smartphone training in reducing urinary tract infection in pediatric clean intermittent catheterization: a prospective study.
Eur J Pediatr
January 2025
Pediatric Nephrology AB, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
Purpose: Study aimed to compare incidence of urinary tract infection (UTI), type of bacteria grown, development of antibiotic resistance over 2 years in children whose caregivers underwent training based on the Roy Adaptation Model with an android phone application for patients clean intermittent catheterization (RAMACIC) versus those whose caregivers received routine training in hospital.
Method: This study was conducted as a descriptive, prospective study with 40 patients and caregivers between October 2021 and 2023 as a continuation of a previously conducted randomized controlled experimental study by the researchers. Data were collected the "Participant Form," and "Urine Test Form" analyzed with the SPSS 22 package.
TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real-World Study.
Cancer Med
January 2025
Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: The 2021 WHO Classification of Central Nervous System Tumors introduces more molecular markers for glioma reclassification, including TERT promoter (TERTp) mutation as a key feature in glioblastoma diagnosis.
Aims: Given the changes in the entities included in each subtype under the new classification, this research investigated the distribution, prognostic value, and correlations with other molecular alterations of TERTp mutation in different subgroups under this latest classification.
Methods: All glioma patients admitted to Peking Union Medical College Hospital for surgical resection or biopsy from 2011 to 2022 were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!